Timing Is Everything As Mereo Still Eyes US Listing
Executive Summary
The London-headquartered firm believes that its efficient control of costs and strong data in support of its investigational treatments for rare respiratory, bone and endocrine diseases will attract investors across the Atlantic once it decides to refile for a listing on the Nasdaq.
You may also be interested in...
Mereo On The Move With Strong COPD Data And US Listing Plan
The UK firm, boosted by promising data for acumapimod for acute exacerbations of COPD, is seeking to conduct an initial public offering in the US.
AZ Licensing Deal Boosts Mereo Orphan Disease Model
UK group Mereo BioPharma is paying a very reasonable $5m to get its hands on AstraZeneca’s Phase II compound for the rare genetic disorder AATD.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.